Form 8-K - Current report:
SEC Accession No. 0001193125-24-252618
Filing Date
2024-11-07
Accepted
2024-11-07 07:45:31
Documents
16
Period of Report
2024-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d835519d8k.htm   iXBRL 8-K 29010
2 EX-99.1 d835519dex991.htm EX-99.1 142221
7 GRAPHIC g835519g1107050606363.jpg GRAPHIC 7150
  Complete submission text file 0001193125-24-252618.txt   367904

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA xoma-20241107.xsd EX-101.SCH 4582
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE xoma-20241107_def.xml EX-101.DEF 14451
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE xoma-20241107_lab.xml EX-101.LAB 24601
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE xoma-20241107_pre.xml EX-101.PRE 15484
19 EXTRACTED XBRL INSTANCE DOCUMENT d835519d8k_htm.xml XML 7796
Mailing Address 2200 POWELL STREET SUITE 310 EMERYVILLE CA 94608
Business Address 2200 POWELL STREET SUITE 310 EMERYVILLE CA 94608 510-204-7239
XOMA Royalty Corp (Filer) CIK: 0000791908 (see all company filings)

EIN.: 522154066 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39801 | Film No.: 241433240
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)